Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
Non Small Cell Lung Cancer NSCLC
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,186 (final count)
- Started
- Jun 1, 2017
- Main results expected
- Mar 12, 2021
- Fully finished
- Nov 15, 2027
- Results posted
- Apr 7, 2022
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS); D + SoC Compared With SoC Alone
Measured over: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).
Overall Survival (OS); D + SoC Compared With SoC Alone
Measured over: From baseline until death due to any cause. Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03164616 · record last updated 2026-03-13 · checked 2026-11-09 15:47 UTC